The JAK1 Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the JAK1 gene in the human 769-P cell line, serving as a loss-of-function model for cytokine signaling studies. This product comprises a heterogeneous pool of cells with distinct JAK1 disruptions, collectively eliminating JAK1 protein expression without clonal selection. It is optimized for investigating JAK-STAT pathway dynamics in a clear cell renal cell carcinoma (ccRCC) background.
The 769-P cell line originates from human clear cell renal cell carcinoma, an epithelial tumor model representative of the most common kidney cancer subtype. These cells retain hallmark ccRCC features such as VHL inactivation and hypoxia-inducible pathway activation. They express cytokine receptors including IL-6R and interferon receptors, providing a physiologically relevant context for JAK1-dependent signaling research. Their adherent growth and stable karyotype facilitate reproducible gene editing and downstream assays.
JAK1 encodes a non-receptor tyrosine kinase that functions immediately downstream of type I and II cytokine receptors. Upon binding of ligands like IL-6, interferon-gamma, IL-2, and IL-15, JAK1 undergoes trans-phosphorylation and forms complexes with receptor subunits and TYK2. Activated JAK1 phosphorylates STAT1, STAT3, and STAT5, which dimerize and translocate to the nucleus to regulate transcription of targets including BCL2, MYC, CCND1, and VEGF. Negative regulation involves SOCS proteins and PTPN1. JAK1 signaling also interfaces with the PI3K-AKT and MAPK pathways, linking cytokine stimulation to cell proliferation and survival.
In ccRCC, aberrant JAK-STAT activation driven by autocrine/paracrine cytokine loops promotes tumor proliferation, apoptosis resistance, and immune evasion. JAK1 disruption in 769-P cells allows dissection of kinase-specific contributions to these oncogenic processes. This model enables assessment of JAK1 dependency in IL-6-induced STAT3 activation, a pathway implicated in ccRCC aggressiveness and metastasis, and supports evaluation of JAK-targeted therapeutics in a disease-relevant cellular setting.
Typical applications include Western blot analysis of JAK1 and phospho-STAT1/3/5 levels, RT-qPCR quantification of BCL2, MYC, CCND1, and VEGF transcripts, and cytokine stimulation assays (e.g., IL-6, interferon-gamma) for phospho-signaling profiling. Dose-response studies with JAK inhibitors probe drug sensitivity, while proliferation and survival assays under cytokine-modulated conditions reveal JAK1-dependent growth mechanisms. These cells also serve as a platform for immune evasion studies and co-culture experiments. For further technical details, please contact Ascent Research.
